Yoichi Yasuda

(−)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells

Masahito Shimizu, Yohei Shirakami, Hiroyasu Sakai et al. · Chemico-Biological Interactions · 2010 · 127 citations

Medicine, Oncology, Pharmacology +12

(–)‐Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor–vascular endothelial growth factor receptor axis

Yohei Shirakami, Masahito Shimizu, Seiji Adachi et al. · Cancer Science · 2009 · 102 citations · Full text

Medicine, Oncology, Pharmacology +16

l-Tryptophan-mediated Enhancement of Susceptibility to Nonalcoholic Fatty Liver Disease Is Dependent on the Mammalian Target of Rapamycin

Yosuke Osawa, Hiromitsu Kanamori, Ekihiro Seki et al. · Journal of Biological Chemistry · 2011 · 89 citations · Full text

Life Sciences, Biochemistry, Pharmacology +12

Preventive Effects of (−)-Epigallocatechin Gallate on Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BL/KsJ-<i>db/db</i> Mice

Masahito Shimizu, Hiroyasu Sakai, Yohei Shirakami et al. · Cancer Prevention Research · 2011 · 78 citations

Medicine, Biochemistry, Pharmacology +15

(−)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRβ and IGF-1R

Yoichi Yasuda, Masahito Shimizu, Hiroyasu Sakai et al. · Chemico-Biological Interactions · 2009 · 65 citations

Life Sciences, Biochemistry, Pharmacology +13